Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness

Published byAlexis Murphy Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness"— Presentation transcript:

1 Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness
Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness. (A) BTSC9 tumor spheres were embedded in a collagen matrix in the presence of 1 μg/mL FTY720 or vehicle (control). Cells invading into the collagen were photographed at the indicated times. (B) After 4 days in the presence of vehicle (control) or of the indicated concentration of FTY720, the area of invasion into collagen was quantitated using the National Institutes of Health ImageJ software. Data are means ± standard deviations from triplicate wells. *Statistically significant difference by Student's t test (P< .01). From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

2 Fig. 5. Combination of FTY720 with TMZ
Fig. 5. Combination of FTY720 with TMZ. (A) MGMT promoter methylation was examined using methylation-specific polymerase chain reaction (U = unmethylated, M = methylated). (B) BTSC9 or BTSC57 were treated with 0.03 μg/mL of FTY720 or 10 μM of TMZ separately or in combination, and after 4 days, viability was measured by MTT assay. Data are means ± standard deviations from triplicate samples. *Statistically significant difference from FTY720 alone. #Statistically significant difference from TMZ alone by Student's t test. (C) BTSC9 were treated with FTY720 (F) or TMZ (T) at the concentrations listed above separately or in combinations, and lysates were immunoblotted for full-length caspase 7 or GAPDH. From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

3 Fig. 6. Combined FTY720 with TMZ in vivo
Fig. 6. Combined FTY720 with TMZ in vivo. (A) Representative MRI of tumors in mice with BTSC9 intracranial xenografts 11 days following injection of cells. Mice were treated with vehicle (control), 10 mg/kg FTY720, 5 mg/kg TMZ, or both. (B) Tumor volume was measured as described in Materials and Methods. Data are means ± standard deviations from 3 mice per group. (C) Survival analysis of mice treated as in panel A (5 mice per group). (D) H & E sections showing lack of invasion and well circumscribed tumors in mice treated with FTY720 plus TMZ, compared with control mice or mice treated with either drug alone. From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

4 Fig. 1. Partial characterization of brain tumor stem cells (BTSCs)
Fig. 1. Partial characterization of brain tumor stem cells (BTSCs). (A) Lysates of the indicated BTSCs were immunoblotted with antibodies specific for CD133. (B) BTSC57 cells were cultured in defined neurosphere medium (NS) or in medium containing 10% FBS. Lysates were blotted for differentiative markers. Longer exposures revealed very low-level GFAP expression in cells grown in neurosphere medium. From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

5 Fig. 2. Induction of apoptosis in brain tumor stem cells (BTSCs) by FTY720. (A) Three different BTSC lines were treated with FTY720 for 4 h at the indicated concentrations. Proliferation was measured using either an MTT assay or WST-1 assay according to instructions. Data are means ± standard deviations of triplicate samples. All FTY720 treatments were statistically significantly different from control by Student's t test (P< .05). Three independent experiments provided similar results. (B) Rat primary astrocytes were treated with the indicated concentrations of FTY720, and viable cells were measured by WST-1 assay. (C) Expression of S1P receptors was examined in BTSC9 and BTSC57 cells using quantitative real-time polymerase chain reaction analysis. From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

6 Fig. 3. Effect of FTY720 on pro- and anti-apoptotic proteins in brain tumor stem cells (BTSCs). BTSC9 (A), BTSC57 (B), or BTSC44 (C) cells were treated with vehicle alone for 3 h (con) or 4 μg/mL FTY720 for the indicated time, and cell lysates were immunoblotted for regulators of apoptosis. Two independent experiments provided similar results. From: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma Neuro Oncol. 2012;14(4): doi: /neuonc/nos005 Neuro Oncol | © The Author(s) Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please

Download ppt "Fig. 4. Effect of FTY720 on brain tumor stem cell (BTSC) invasiveness"

Similar presentations

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Figure 6. Biochemical analysis of mTORC1- and mTORC2-dependent signaling in response to UVB. iRicKO cells were treated with vehicle or with 4OHT for 3.

Figure 6. Biochemical analysis of mTORC1- and mTORC2-dependent signaling in response to UVB. iRicKO cells were treated with vehicle or with 4OHT for 3.
Figure 6. Effect of Withaferin A (WA) treatment on leptin-induced signaling in breast cancer cells. A) Immunoblotting for pSTAT3 (Tyr705), total STAT3,

Figure 6. Effect of Withaferin A (WA) treatment on leptin-induced signaling in breast cancer cells. A) Immunoblotting for pSTAT3 (Tyr705), total STAT3,
Fig. 1 Anti-inflammatory drug treatment reduces the number of reactive microglia in the hippocampus of APPV717I mice. APPV717I transgenic mice (10 months.

Fig. 1 Anti-inflammatory drug treatment reduces the number of reactive microglia in the hippocampus of APPV717I mice. APPV717I transgenic mice (10 months.
Figure 4. Naturally occurring senescent cells from a HER2-expressing patient-derived xenograft secrete IL-6, which is required for tumor growth. A ) A.

Figure 4. Naturally occurring senescent cells from a HER2-expressing patient-derived xenograft secrete IL-6, which is required for tumor growth. A ) A.
Figure 5. Targeted inhibition of DNMT enzymes reduces the fibrotic markers collagen and ASMA. The impact of reducing DNMT levels on the expression of fibrosis-related.

Figure 5. Targeted inhibition of DNMT enzymes reduces the fibrotic markers collagen and ASMA. The impact of reducing DNMT levels on the expression of fibrosis-related.
Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,

Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,
Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.

Fig. 1 Increased MIR155HG expression correlates with glioma grade and mesenchymal transition and confers a poor prognosis in GBM patients. (A) The level.
Figure 1. Validation of BCP rat models (A) Radiological images of the MRMT-1-injected and Hank’s buffer-injected left hindpaw of the rats, 21 days after.

Figure 1. Validation of BCP rat models (A) Radiological images of the MRMT-1-injected and Hank’s buffer-injected left hindpaw of the rats, 21 days after.
Fig. 1. Serum activity of the osteoclast-specific enzyme TRAP-5b and serum levels of RANKL and OPG, key regulators involved in osteoclast differentiation.

Fig. 1. Serum activity of the osteoclast-specific enzyme TRAP-5b and serum levels of RANKL and OPG, key regulators involved in osteoclast differentiation.
Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.

Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM

Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Corresponding author:

Corresponding author:
Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP.

Fig. 6. Knockdown of TCF-4 inhibits TCTP-induced glioma cell proliferation in vitro and in vivo. (A) TCF-4 was knocked down in U-251/TCTP and H-4/TCTP.
Drug concentration (μM)

Drug concentration (μM)
Fig. 1 Selection of patients

Fig. 1 Selection of patients
Figure 1. Phenotypic and functional characterization of nasopharyngeal carcinoma (NPC)– and healthy donor (HD)–derived exosomes. A) Electron microscopy.

Figure 1. Phenotypic and functional characterization of nasopharyngeal carcinoma (NPC)– and healthy donor (HD)–derived exosomes. A) Electron microscopy.
Fig. 4. TR3-dependent induction of ATF3 by DIM-C-pPhOCH 3 in human pancreatic cancer cells. ( A ) Induction of ATF3 by DIM-C-pPhOCH 3

Fig. 4. TR3-dependent induction of ATF3 by DIM-C-pPhOCH 3 in human pancreatic cancer cells. ( A ) Induction of ATF3 by DIM-C-pPhOCH 3

Similar presentations

Ads by Google